伦丁南通过调节AKT/Nur77/Bcl-2信号轴来抑制黑色素瘤的发展
Xuebin Lai1, Yanling Chen1, Rongjie Huang2
1Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian 363000, People's Republic of China.
Journal of Cancer
|January 2, 2025
概括
来自Lentinus edodes的Lentinan (LNT) 通过诱导亡来抑制黑色素瘤的生长. 它调节AKT/Nur77/Bcl-2通路,显示了黑色素瘤治疗和药物开发的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 自然产品研究 自然产品研究
背景情况:
- 黑色素瘤是一种具有挑战性的皮肤癌,对天然产品治疗的研究正在进行中.
- 伦丁南 (LNT),源自Lentinus edodes,显示出显著的抗瘤特性.
- 研究LNT的药理作用为黑色素瘤提供了一个新的治疗策略.
研究的目的:
- 为了评估Lentinan (LNT) 的抗黑色素瘤作用.
- 阐明LNT抗瘤活性背后的分子机制.
- 确定LNT作为黑色素瘤的潜在治疗剂.
主要方法:
- 建立一种带有黑色素瘤瘤的小鼠模型,用于增长评估.
- 在体外分析B16F10细胞增殖,使用细胞计数组-8试验.
- 西方涂抹,组织学染色和细胞染色以评估分子表达和局部化.
主要成果:
- 在体外和体外,LNT显著抑制了黑色素瘤细胞的生长和增殖.
- LNT调节的关键蛋白质:降低了多 (ADP 核糖) 聚合酶1和增殖细胞核抗原,降低了Nur77和增加了Bcl-2.
- 通过促进Nur77/Bcl-2相互作用,涉及AKT通路,LNT诱导了亡.
结论:
- 伦丁南可以抑制黑色素瘤瘤的生长,并通过AKT/Nur77/Bcl-2通路促进亡.
- LNT显示了黑色素瘤药物开发和临床应用的巨大潜力.
- 用LNT准AKT/Nur77/Bcl-2通路为黑色素瘤提供了一个有前途的治疗途径.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
721
相关概念视频
01:31The Intrinsic Apoptotic Pathway
5.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.5K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
02:34Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K